Asymchem Laboratories (Tianjin) Co., Ltd. and AUM Biosciences Pte. Ltd. announced a collaboration agreement. Under the terms of the agreement, AUM and Asymchem agree to collaborate on the process development, and the clinical and commercial production, of AUM 601, which is a highly selective oral small molecule inhibitor of the tropomyosin receptor kinase (TRK) for treating rare cancers.